Literature DB >> 11227132

Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients.

N Rösler1, I Wichart, K A Jellinger.   

Abstract

OBJECTIVES: In view of contradictory findings in previous studies, to examine the diagnostic value of interleukin-6 measurements in cerebrospinal fluid (CSF) of Alzheimer's disease patients.
MATERIAL AND METHODS: Interleukin-6-immunoreactivity (IL-6-IR) was measured in 169 intra vitam lumbar and 21 post mortem ventricular CSF samples of patients with probable and neuropathologically confirmed Alzheimer's disease (AD), non-AD dementias (NAD), neurological disorders without cognitive impairment (OND) and controls (CON) using a specific sandwich enzyme immunoassay.
RESULTS: Intra vitam lumbar samples had significantly elevated (P < 0.03) IL-6-IR not only in the AD, but also in the NAD and OND group compared with controls. AD patients with late onset (> 65 years) had slightly (P > 0.05) higher values than patients with early onset (< 65 years). In post mortem ventricular fluid, differences among groups did not reach significance (P > 0.05).
CONCLUSION: We conclude that elevations of CSF IL-6-IR can not serve as a diagnostic marker of the disease, but, hypothetically, could reflect presence or activity of IL-6 mediated immunological phenomena in single AD patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11227132     DOI: 10.1034/j.1600-0404.2001.103002126.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

Review 1.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Intrathecal levels of IL-6 in Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

Review 4.  Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.

Authors:  Wen-Ying Wang; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-06

Review 5.  Cognitive dysfunction and diabetes mellitus.

Authors:  Christopher T Kodl; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 6.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.